Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2016, Article ID 1295092, 3 pages
http://dx.doi.org/10.1155/2016/1295092
Case Report

Successful Control of Massive Bleeding in a Child with Burkitt’s Lymphoma via a Biosimilar Recombinant Activated Factor VII (AryoSeven)

Paediatric Congenital Hematologic Disorders Research Center, Shahid Beheshti University of Medical Sciences, Tehran 15514-15468, Iran

Received 13 December 2015; Revised 27 April 2016; Accepted 28 April 2016

Academic Editor: Kate Khair

Copyright © 2016 Kourosh Goudarzi Pour et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. C. Logan and L. T. Goodnough, “Recombinant factor VIIa: an assessment of evidence regarding its efficacy and safety in the off-label setting,” Hematology, vol. 2010, pp. 153–159, 2010. View at Google Scholar · View at Scopus
  2. U. Hedner, “Mechanism of action of factor VIIa in the treatment of coagulopathies,” Seminars in Thrombosis and Hemostasis, vol. 32, no. 1, pp. 77–85, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Faranoush, H. Abolghasemi, G. Toogeh et al., “A comparison between recombinant activated factor VII (Aryoseven) and Novoseven in patients with congenital factor VII deficiency,” Clinical and Applied Thrombosis/Hemostasis, vol. 21, no. 8, pp. 724–728, 2015. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Faranoush, H. Abolghasemi, F. Mahboudi et al., “A comparison of efficacy between recombinant activated factor VII (Aryoseven) and Novoseven in patients with hereditary FVIII deficiency with inhibitor,” Clinical and Applied Thrombosis/Hemostasis, vol. 22, no. 2, pp. 184–190, 2016. View at Publisher · View at Google Scholar · View at Scopus
  5. J. H. Lee, H. J. Ng, and M. Y. Chan, “Use of recombinant factor VIIa in gastrointestinal bleeding in children with malignancies: a case series,” Proceedings of Singapore Healthcare, vol. 19, no. 2, pp. 159–162, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. H. Jen and S. Shew, “Recombinant activated factor VII use in critically ill infants with active hemorrhage,” Journal of Pediatric Surgery, vol. 43, no. 12, pp. 2235–2238, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. J. P. Cello and M. F. Chan, “Octreotide therapy for variceal hemorrhage,” Digestion, vol. 54, no. 1, pp. 20–26, 1993. View at Google Scholar · View at Scopus
  8. J.-L. Vincent, R. Rossaint, B. Riou, Y. Ozier, D. Zideman, and D. R. Spahn, “Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding—a European perspective,” Critical Care, vol. 10, no. 4, article R120, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. B. Brenner, R. Hoffman, D. Balashov, E. Shutluko, S. Čulić, and E. Nizamoutdinova, “Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated factor VII,” Clinical and Applied Thrombosis/Hemostasis, vol. 11, no. 4, pp. 401–410, 2005. View at Publisher · View at Google Scholar · View at Scopus